scholarly journals Stereo-selective binding of monoclonal antibodies to the poly-gamma-d-glutamic acid capsular antigen of Bacillus anthracis

2013 ◽  
Vol 55 (3-4) ◽  
pp. 337-344 ◽  
Author(s):  
Mark A. Hubbard ◽  
Peter Thorkildson ◽  
William H. Welch ◽  
Thomas R. Kozel
2009 ◽  
Vol 64 (2) ◽  
pp. 229-232 ◽  
Author(s):  
David P. AuCoin ◽  
Marjorie D. Sutherland ◽  
Ann L. Percival ◽  
C. Rick Lyons ◽  
Julie A. Lovchik ◽  
...  

2008 ◽  
Vol 76 (3) ◽  
pp. 899-906 ◽  
Author(s):  
Marjorie D. Sutherland ◽  
Peter Thorkildson ◽  
Samuel D. Parks ◽  
Thomas R. Kozel

ABSTRACT Bacillus anthracis is surrounded by an antiphagocytic capsule composed of poly-γ-d-glutamic acid (γDPGA). Bacterial and fungal capsular polysaccharides are shed into body fluids in large amounts during infection. The goal of our study was to examine the in vivo fate and distribution of the γDPGA capsular polypeptide. Mice were injected via the intravenous route with various amounts of purified γDPGA. Blood, urine, and various organs were harvested at different times after treatment. Sites of γDPGA accumulation were determined by immunoassay using monoclonal antibodies specific for γDPGA. The results showed that the liver and spleen were the primary sites for the accumulation of γDPGA. As found in previous studies of capsular polysaccharides, the Kupffer cells of the liver and splenic macrophages were sites for the cellular accumulation of γDPGA. Unlike capsular polysaccharides, the hepatic sinusoidal endothelial cells were also sites for γDPGA accumulation. γDPGA was rapidly cleared from serum and was excreted into the urine. γDPGA in the urine showed a reduced molecular size relative to native γDPGA. The results indicate that in vivo clearance of the polypeptide capsular antigen of B. anthracis shares several features with the clearance of capsular polysaccharides. Key differences between the in vivo behaviors of γDPGA and capsular polysaccharides include the accumulation of γDPGA in hepatic sinusoidal endothelial cells and a γDPGA clearance rate that was more rapid than the clearance reported for capsular polysaccharides.


2013 ◽  
Vol 9 (4) ◽  
pp. e1003306 ◽  
Author(s):  
Maria Hovenden ◽  
Mark A. Hubbard ◽  
David P. AuCoin ◽  
Peter Thorkildson ◽  
Dana E. Reed ◽  
...  

2015 ◽  
Vol 197 (11) ◽  
pp. 1854-1861 ◽  
Author(s):  
So-Young Oh ◽  
Stefan G. Richter ◽  
Dominique M. Missiakas ◽  
Olaf Schneewind

ABSTRACTd-Glutamate is an essential component of bacterial peptidoglycan and a building block of the poly-γ-d-glutamic acid (PDGA) capsule ofBacillus anthracis, the causative agent of anthrax. Earlier work suggested that two glutamate racemases, encoded byracE1andracE2, are each essential for growth ofB. anthracis, supplyingd-glutamic acid for the synthesis of peptidoglycan and PDGA capsule. Earlier work could not explain, however, why two enzymes that catalyze the same reaction may be needed for bacterial growth. Here, we report that deletion ofracE1orracE2did not prevent growth ofB. anthracisSterne (pXO1+pXO2−), the noncapsulating vaccine strain, or ofB. anthracisAmes (pXO1+pXO2+), a fully virulent, capsulating isolate. While mutants with deletions inracE1andracE2were not viable,racE2deletion delayed vegetative growth ofB. anthracisfollowing spore germination and caused aberrant cell shapes, phenotypes that were partially restored by exogenousd-glutamate. Deletion ofracE1orracE2fromB. anthracisAmes did not affect the production or stereochemical composition of the PDGA capsule. A model is presented wherebyB. anthracis, similar toBacillus subtilis, utilizes two functionally redundant racemase enzymes to synthesized-glutamic acid for peptidoglycan synthesis.IMPORTANCEGlutamate racemases, enzymes that convertl-glutamate tod-glutamate, are targeted for antibiotic development. Glutamate racemase inhibitors may be useful for the treatment of bacterial infections such as anthrax, where the causative agent,B. anthracis, requiresd-glutamate for the synthesis of peptidoglycan and poly-γ-d-glutamic acid (PDGA) capsule. Here we show thatB. anthracispossesses two glutamate racemase genes that can be deleted without abolishing either bacterial growth or PDGA synthesis. These data indicate that drug candidates must inhibit both glutamate racemases, RacE1 and RacE2, in order to blockB. anthracisgrowth and achieve therapeutic efficacy.


2020 ◽  
Vol 204 (5) ◽  
pp. 1263-1273 ◽  
Author(s):  
Tanya M. Jelacic ◽  
Wilson J. Ribot ◽  
Jennifer Chua ◽  
Anne E. Boyer ◽  
Adrian R. Woolfitt ◽  
...  

Cytokine ◽  
2018 ◽  
Vol 110 ◽  
pp. 350-356 ◽  
Author(s):  
Jun Ho Jeon ◽  
Deok-Bum Park ◽  
Sun-Je Woo ◽  
Hae-Ri Lee ◽  
Ok-Kyu Park ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document